Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mutant protein tackles DNA guardian to promote cancer development

07.11.2018

Melbourne scientists have discovered how tumour development is driven by mutations in the most important gene in preventing cancer, p53

Melbourne scientists have discovered how tumour development is driven by mutations in the most important gene in preventing cancer, p53.


Biomedical animation of a breast tumour

Credit: Drew Berry, Walter and Eliza Hall Institute

The research revealed that in the early stages of cancer, mutant p53 'tackles' the normal p53 protein and blocks it from carrying out its protective role. As a result, p53 can no longer activate natural defences against cancer - such as the body's DNA repair process - increasing the risk of cancer developing.

The research was led by Dr Brandon Aubrey, Professor Andreas Strasser and Dr Gemma Kelly together with bioinformaticians Professor Gordon Smyth and Dr Yunshun Chen. The findings are published in this month's edition of Genes and Development.

At a glance

  • Researchers have discovered how mutations in p53 - found in half of all human cancers - drive cancer development.
  • The mutant p53 protein 'tackles' the normal protein and prevents it from carrying out its protective role, while permitting it to activate genes driving tumour growth.
  • The team is now examining whether the mutant p53 protein acts in the same way in established tumours, with important implications for cancer therapy.

Tackling DNA's guardian

p53 is known as the 'guardian of the genome' due to its role in protecting cells from cancer.

"p53 plays a critical role in many pathways that prevent cancer, such as repairing DNA or killing cells if they have irreparable DNA damage," Dr Kelly said.

"Genetic defects in p53 are found in half of all human cancers, but exactly how these changes disrupt p53 function has long been a mystery."

Dr Kelly said that cells normally have two copies of the p53 gene in every cell.

"Early during cancer development, one copy of the gene may undergo a sudden and permanent change through mutation, while the other copy of the gene remains normal. This results in the cell making a mixture of normal and mutant versions of the p53 protein.

"We found that the mutant p53 protein can bind to and 'tackle' the normal p53 protein, blocking it from performing protective roles such as DNA repair. This makes the cell more likely to undergo further genetic changes that accelerate tumour development."

The team expected the mutant proteins would block all normal p53 activity, so was surprised to find that only certain p53-dependent pathways were affected.

"The mutant proteins are cunning: while they stop p53 from activating pathways that protect against cancer, they still allow p53 to activate pathways that promote tumour growth. p53's role in cancer is clearly more complicated than we had expected," Dr Kelly said.

A mystery resolved

Professor Strasser said the findings inform a longstanding debate about mutant p53.

"Scientists have been debating how mutant p53 contributes to the development of cancer for decades.

"One camp argues that mutant p53 acts by 'tackling' the normal protein and blocking its natural protective roles. The other camp argues that mutant p53 goes 'rogue' and performs new roles that promote tumour development."

"Our work clearly shows that during cancer development, the 'tackling' of normal p53 is most significant. This selectively disables certain but not all normal functions of p53," Professor Strasser said.

Clinical implications

The team is now investigating whether the same is true for established tumours, with important implications for drug treatments.

"Established tumours have often lost the normal copy of their p53 gene and only produce mutant p53 protein," Dr Kelly said.

"If mutant p53 acts by tackling normal p53, then it may no longer play a role in established tumours where no normal p53 is produced. This would mean that drugs that block mutant p53 would have no clinical benefit," she said.

"Conversely, if mutant p53 has new, cancer-promoting activities of its own in established tumours, then a drug that specifically blocks mutant p53 could be beneficial for treating thousands of patients."

###

This work was supported by the Leukaemia Foundation, the Australian National Health and Medical Research Council, the Leukemia and Lymphoma Society of America, the Cancer Council of Victoria, the Victorian Cancer Agency, the Estate of Anthony (Toni) William Redstone OAM, the Craig Perkins Cancer Research Foundation, the Victorian State Government and the Australian Government.

Media Contact

Arunee Wilson
wilson.a@wehi.edu.au
61-393-452-719

 @WEHI_research

http://www.wehi.edu.au/ 

Arunee Wilson | EurekAlert!
Further information:
http://dx.doi.org/10.1101/gad.314286.118

Further reports about: CANCER DNA DNA repair cancer development mutant p53 p53 p53 gene tumour tumour growth

More articles from Life Sciences:

nachricht When predictions of theoretical chemists become reality
22.05.2020 | Technische Universität Dresden

nachricht From artificial meat to fine-tuning photosynthesis: Food System Innovation – and how to get there
20.05.2020 | Potsdam-Institut für Klimafolgenforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: When predictions of theoretical chemists become reality

Thomas Heine, Professor of Theoretical Chemistry at TU Dresden, together with his team, first predicted a topological 2D polymer in 2019. Only one year later, an international team led by Italian researchers was able to synthesize these materials and experimentally prove their topological properties. For the renowned journal Nature Materials, this was the occasion to invite Thomas Heine to a News and Views article, which was published this week. Under the title "Making 2D Topological Polymers a reality" Prof. Heine describes how his theory became a reality.

Ultrathin materials are extremely interesting as building blocks for next generation nano electronic devices, as it is much easier to make circuits and other...

Im Focus: Rolling into the deep

Scientists took a leukocyte as the blueprint and developed a microrobot that has the size, shape and moving capabilities of a white blood cell. Simulating a blood vessel in a laboratory setting, they succeeded in magnetically navigating the ball-shaped microroller through this dynamic and dense environment. The drug-delivery vehicle withstood the simulated blood flow, pushing the developments in targeted drug delivery a step further: inside the body, there is no better access route to all tissues and organs than the circulatory system. A robot that could actually travel through this finely woven web would revolutionize the minimally-invasive treatment of illnesses.

A team of scientists from the Max Planck Institute for Intelligent Systems (MPI-IS) in Stuttgart invented a tiny microrobot that resembles a white blood cell...

Im Focus: NASA's Curiosity rover finds clues to chilly ancient Mars buried in rocks

By studying the chemical elements on Mars today -- including carbon and oxygen -- scientists can work backwards to piece together the history of a planet that once had the conditions necessary to support life.

Weaving this story, element by element, from roughly 140 million miles (225 million kilometers) away is a painstaking process. But scientists aren't the type...

Im Focus: Making quantum 'waves' in ultrathin materials

Study co-led by Berkeley Lab reveals how wavelike plasmons could power up a new class of sensing and photochemical technologies at the nanoscale

Wavelike, collective oscillations of electrons known as "plasmons" are very important for determining the optical and electronic properties of metals.

Im Focus: When proteins work together, but travel alone

Proteins, the microscopic “workhorses” that perform all the functions essential to life, are team players: in order to do their job, they often need to assemble into precise structures called protein complexes. These complexes, however, can be dynamic and short-lived, with proteins coming together but disbanding soon after.

In a new paper published in PNAS, researchers from the Max Planck Institute for Dynamics and Self-Organization, the University of Oxford, and Sorbonne...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Dresden Nexus Conference 2020: Same Time, Virtual Format, Registration Opened

19.05.2020 | Event News

Aachen Machine Tool Colloquium AWK'21 will take place on June 10 and 11, 2021

07.04.2020 | Event News

International Coral Reef Symposium in Bremen Postponed by a Year

06.04.2020 | Event News

 
Latest News

New gravitational-wave model can bring neutron stars into even sharper focus

22.05.2020 | Physics and Astronomy

A replaceable, more efficient filter for N95 masks

22.05.2020 | Materials Sciences

Capturing the coordinated dance between electrons and nuclei in a light-excited molecule

22.05.2020 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>